The pursuit of effective and well-tolerated treatments for mental health disorders and neurological ailments has been a formidable challenge. Traditional medications often carry a burden of side effects, limiting their efficacy for numerous patients. Bright Minds Biosciences, a burgeoning preclinical biotech company, is emerging as a beacon of optimism in this realm.